SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on July 20, 2020, covering events occurring on July 17, 2020. The registrant is a Delaware corporation with principal executive offices in Westport, Connecticut, and its common stock trades on the NASDAQ Capital Market under the symbol BSGM. The filing does not pertain to Streamex Corp. as indicated in the request metadata; the actual registrant is BioSig Technologies, Inc.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing focuses solely on a corporate event regarding executive participation in an industry summit.
Outlook, Commentary, and Risks
Under Item 8.01 (Other Events), the Company announced that Jerry Zeldis, M.D., Ph.D., Chief Medical Officer of ViralClear Pharmaceuticals, Inc. (a majority-owned subsidiary), will participate in the B Riley FBR Infectious Disease Summit on July 21, 2020. No specific guidance, risk factors, or unusual items are detailed within the body of this 8-K, though the press release referenced as Exhibit 99.1 may contain further details.
Key Facts for Investor Verification
- Verify the actual registrant name is BioSig Technologies, Inc., not Streamex Corp.
- Confirm the date and agenda of the B Riley FBR Infectious Disease Summit participation by Dr. Jerry Zeldis.
- Review Exhibit 99.1 (Press Release) for specific details on the presentation content.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial metrics.